What is Imbio?
Imbio specializes in AI-driven medical imaging analysis, focusing on enhancing personalized medicine for lung and cardiothoracic conditions. Their advanced algorithms provide critical insights for pulmonary hypertension and coronary calcification, serving physicians, health systems, and patients. By collaborating with medical device and pharmaceutical companies, Imbio develops bespoke imaging solutions that support disease-specific therapies. The company's commitment to secure, scalable, and interoperable deployment options ensures improved patient care and management, positioning them as a trusted global entity in diagnostic innovation.
How much funding has Imbio raised?
Imbio has raised a total of $2.7M across 3 funding rounds:
Private Equity
$1.1M
Series A
$1.5M
Debt
$150K
Private Equity (2015): $1.1M, investors not publicly disclosed
Series A (2017): $1.5M led by Invenshure
Debt (2020): $150K supported by PPP
Key Investors in Imbio
Invenshure
Invenshure is dedicated to transforming challenging problems into successful companies by leveraging institutional intellectual property. Their early-stage model focuses on delivering returns to investors while contributing positively to society.
What's next for Imbio?
With a recent major strategic investment, Imbio is poised for accelerated growth and market penetration. The company is expected to leverage this capital to further refine its AI diagnostic tools, expand its research and development capabilities, and forge new partnerships within the healthcare ecosystem. Future initiatives will likely focus on broadening the application of their imaging analysis across a wider range of medical specialties and enhancing the integration of their solutions into existing clinical workflows, solidifying their role in the advancement of precision medicine.
See full Imbio company page
